Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,099 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
Choi J, Lee JE, Choi CM, Oh IJ, Lee KY, Jang TW, Lee SH, Kim EY, Park DW, Park SH, Lee SY. Choi J, et al. Among authors: lee sh, lee sy, lee je, lee ky. Thorac Cancer. 2022 Dec;13(23):3431-3435. doi: 10.1111/1759-7714.14663. Epub 2022 Oct 19. Thorac Cancer. 2022. PMID: 36259253 Free PMC article. Clinical Trial.
Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE, Kim SY. Kim HJ, et al. Among authors: lee sy, lee jc, lee je, lee ky, lee mk, lee gh. Lung Cancer. 2012 Mar;75(3):321-5. doi: 10.1016/j.lungcan.2011.08.005. Epub 2011 Sep 17. Lung Cancer. 2012. PMID: 21930325
Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment.
Kim HR, Lee JC, Kim YC, Kim KS, Oh IJ, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Ryu JS, Jang SH, Son JW, Lee JE, Kim SY, Kim HJ, Lee KY. Kim HR, et al. Among authors: lee sy, lee jc, lee je, lee mk, lee ky, lee gh. Lung Cancer. 2014 Feb;83(2):252-8. doi: 10.1016/j.lungcan.2013.11.008. Epub 2013 Nov 20. Lung Cancer. 2014. PMID: 24309368
Spontaneous regression in advanced squamous cell lung carcinoma.
Park YH, Park BM, Park SY, Choi JW, Kim SY, Kim JO, Jung SS, Park HS, Moon JY, Lee JE. Park YH, et al. Among authors: lee je. J Thorac Dis. 2016 Mar;8(3):E235-9. doi: 10.21037/jtd.2016.02.19. J Thorac Dis. 2016. PMID: 27076978 Free PMC article.
Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance.
Lee JE, Park HS, Lee D, Yoo G, Kim T, Jeon H, Yeo MK, Lee CS, Moon JY, Jung SS, Kim JO, Kim SY, Park DI, Park YH, Lee JC, Oh IJ, Lim DS, Chung C. Lee JE, et al. Among authors: lee d, lee jc, lee cs. Biochem Biophys Res Commun. 2016 May 20;474(1):154-160. doi: 10.1016/j.bbrc.2016.04.089. Epub 2016 Apr 20. Biochem Biophys Res Commun. 2016. PMID: 27105908
Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.
Nam Y, Kim HC, Kim YC, Jang SH, Lee KY, Lee SY, Lee SH, Lee SY, Yoon SH, Ryu JS, Jang TW, Chang YS, Kim SJ, Park CK, Lee JE, Jung CY, Choi CM. Nam Y, et al. Among authors: lee sh, lee sy, lee je, lee ky. Thorac Cancer. 2021 Mar;12(6):890-898. doi: 10.1111/1759-7714.13857. Epub 2021 Feb 2. Thorac Cancer. 2021. PMID: 33529490 Free PMC article.
5,099 results